This provider's $8.4M in total Medicare payments ranks in the 98th percentile of Ophthalmology providers nationally.
Medicare payments to this provider grew 306% from 2014 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 85% in 2017
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $223.94 | $144.16 | 1.55x | $79.78 | $336.0K | 4.2K | 2.1K |
| 2015 | $374.17 | $128.24 | 2.92x | $245.93 | $293.4K | 3.5K | 1.9K |
| 2016 | $214.28 | $153.19 | 1.40x | $61.09 | $361.0K | 3.6K | 2.0K |
| 2017 | $493.71 | $155.38 | 3.18x | $338.33 | $667.9K | 5.9K | 2.9K |
| 2018 | $631.93 | $165.75 | 3.81x | $466.18 | $943.7K | 7.5K | 3.7K |
| 2019 | $786.17 | $212.64 | 3.70x | $573.53 | $1.1M | 8.3K | 3.9K |
| 2020 | $642.88 | $174.76 | 3.68x | $468.12 | $1.0M | 8.0K | 3.5K |
| 2021 | $659.18 | $179.88 | 3.66x | $479.30 | $1.2M | 8.6K | 3.7K |
| 2022 | $884.47 | $235.26 | 3.76x | $649.21 | $1.1M | 7.9K | 3.2K |
| 2023 | $1.0K | $323.99 | 3.16x | $700.58 | $1.4M | 8.4K | 3.6K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 5.4K | $4.0M | $730.54 | 3.26x |
| 67028 | Injection of drug into eye | 9.5K | $866.7K | $91.56 | 3.59x |
| 92134 | Diagnostic imaging of retina | 16.6K | $529.7K | $31.88 | 3.79x |
| J3590 | Unclassified biologics | 623 | $464.7K | $745.97 | 2.83x |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | 7.1K | $433.4K | $61.43 | 3.81x |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | 4.4K | $395.0K | $89.80 | 3.81x |
| J2778 | Injection, ranibizumab, 0.1 mg | 1.2K | $344.3K | $297.60 | 2.57x |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | 2.7K | $221.6K | $81.34 | 3.14x |
| J0179 | Injection, brolucizumab-dbll, 1 mg | 660 | $164.6K | $249.38 | 2.92x |
| 67042 | Removal of membrane from the retina, pars plana approach | 132 | $123.0K | $932.14 | 3.49x |
| J3490 | Unclassified drugs | 55 | $97.6K | $1.8K | 2.79x |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | 863 | $93.3K | $108.13 | 3.84x |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 534 | $82.3K | $154.15 | 3.21x |
| 92235 | Examination of retinal blood vessels by ophthalmoscope | 1.0K | $78.6K | $78.58 | 3.58x |
| 92250 | Photography of the retina | 1.6K | $66.4K | $40.33 | 3.59x |
| 76512 | Ultrasound of eye disease, growth, or structure | 1.2K | $61.7K | $50.51 | 3.63x |
| 92226 | Examination of eye by ophthalmoscope with retinal drawing | 2.9K | $58.0K | $19.84 | 3.54x |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | 451 | $55.3K | $122.71 | 2.57x |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | 614 | $47.1K | $76.79 | 3.79x |
| 92202 | Extended examination of eye with drawing of optic nerve and surrounding area (macula) | 3.8K | $45.6K | $12.04 | 4.07x |
This provider submits charges 3.33 times higher than what Medicare actually pays.
A markup ratio of 3.33x means for every $100 Medicare pays, this provider initially charges $333. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Ophthalmology providers in NV for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Arshad Khanani, M.D. | Reno, NV | $42.4M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data